vs
Side-by-side financial comparison of BayCom Corp (BCML) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
BayCom Corp is the larger business by last-quarter revenue ($25.9M vs $21.9M, roughly 1.2× Cue Biopharma, Inc.). BayCom Corp runs the higher net margin — 26.5% vs 7.2%, a 19.3% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 9.4%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 2.9%).
BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
BCML vs CUE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $21.9M |
| Net Profit | $6.9M | $1.6M |
| Gross Margin | — | — |
| Operating Margin | 36.6% | 9.0% |
| Net Margin | 26.5% | 7.2% |
| Revenue YoY | 9.4% | 1292.3% |
| Net Profit YoY | 12.1% | 116.7% |
| EPS (diluted) | $0.63 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.9M | $21.9M | ||
| Q3 25 | $25.7M | $2.1M | ||
| Q2 25 | $24.7M | $3.0M | ||
| Q1 25 | $24.3M | $421.0K | ||
| Q4 24 | $23.7M | $1.6M | ||
| Q3 24 | $25.6M | $3.3M | ||
| Q2 24 | $23.8M | $2.7M | ||
| Q1 24 | $24.5M | $1.7M |
| Q4 25 | $6.9M | $1.6M | ||
| Q3 25 | $5.0M | $-7.4M | ||
| Q2 25 | $6.4M | $-8.5M | ||
| Q1 25 | $5.7M | $-12.3M | ||
| Q4 24 | $6.1M | — | ||
| Q3 24 | $6.0M | $-8.7M | ||
| Q2 24 | $5.6M | $-10.2M | ||
| Q1 24 | $5.9M | $-12.3M |
| Q4 25 | 36.6% | 9.0% | ||
| Q3 25 | 26.3% | -353.4% | ||
| Q2 25 | 35.3% | -292.3% | ||
| Q1 25 | 31.6% | -2921.4% | ||
| Q4 24 | 34.2% | — | ||
| Q3 24 | 32.4% | -264.2% | ||
| Q2 24 | 31.9% | -390.6% | ||
| Q1 24 | 33.3% | -737.8% |
| Q4 25 | 26.5% | 7.2% | ||
| Q3 25 | 19.5% | -346.6% | ||
| Q2 25 | 25.8% | -287.1% | ||
| Q1 25 | 23.4% | -2911.4% | ||
| Q4 24 | 25.9% | — | ||
| Q3 24 | 23.5% | -259.6% | ||
| Q2 24 | 23.6% | -382.7% | ||
| Q1 24 | 24.0% | -719.1% |
| Q4 25 | $0.63 | $0.05 | ||
| Q3 25 | $0.46 | $-0.07 | ||
| Q2 25 | $0.58 | $-0.09 | ||
| Q1 25 | $0.51 | $-0.17 | ||
| Q4 24 | $0.55 | — | ||
| Q3 24 | $0.54 | $-0.17 | ||
| Q2 24 | $0.50 | $-0.20 | ||
| Q1 24 | $0.51 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $27.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.6M | $26.4M |
| Total Assets | $2.6B | $42.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $27.1M | ||
| Q3 25 | — | $11.7M | ||
| Q2 25 | — | $27.5M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | — | $22.5M | ||
| Q3 24 | — | $32.4M | ||
| Q2 24 | — | $30.0M | ||
| Q1 24 | — | $41.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.0M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $3.0M |
| Q4 25 | $338.6M | $26.4M | ||
| Q3 25 | $334.3M | $13.2M | ||
| Q2 25 | $330.6M | $18.2M | ||
| Q1 25 | $329.3M | $6.6M | ||
| Q4 24 | $324.4M | $17.5M | ||
| Q3 24 | $321.7M | $25.4M | ||
| Q2 24 | $315.3M | $21.6M | ||
| Q1 24 | $314.2M | $30.0M |
| Q4 25 | $2.6B | $42.2M | ||
| Q3 25 | $2.6B | $31.6M | ||
| Q2 25 | $2.6B | $40.7M | ||
| Q1 25 | $2.6B | $22.3M | ||
| Q4 24 | $2.7B | $32.2M | ||
| Q3 24 | $2.6B | $44.8M | ||
| Q2 24 | $2.6B | $42.3M | ||
| Q1 24 | $2.6B | $54.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.09× | ||
| Q1 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.8M | $-1.1M |
| Free Cash FlowOCF − Capex | $30.1M | — |
| FCF MarginFCF / Revenue | 116.2% | — |
| Capex IntensityCapex / Revenue | 6.7% | 0.0% |
| Cash ConversionOCF / Net Profit | 4.64× | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | $51.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | $-1.1M | ||
| Q3 25 | $7.3M | $-9.0M | ||
| Q2 25 | $6.4M | $-3.4M | ||
| Q1 25 | $9.3M | $-8.2M | ||
| Q4 24 | $30.4M | $-36.3M | ||
| Q3 24 | $9.6M | $-7.5M | ||
| Q2 24 | $7.7M | $-10.0M | ||
| Q1 24 | $5.1M | $-9.8M |
| Q4 25 | $30.1M | — | ||
| Q3 25 | $6.2M | — | ||
| Q2 25 | $5.6M | $-3.4M | ||
| Q1 25 | $9.1M | $-8.3M | ||
| Q4 24 | $28.7M | $-36.4M | ||
| Q3 24 | $9.4M | $-7.5M | ||
| Q2 24 | $7.4M | $-10.0M | ||
| Q1 24 | $3.9M | $-9.8M |
| Q4 25 | 116.2% | — | ||
| Q3 25 | 24.3% | — | ||
| Q2 25 | 22.8% | -116.5% | ||
| Q1 25 | 37.6% | -1976.7% | ||
| Q4 24 | 121.1% | -2309.3% | ||
| Q3 24 | 36.6% | -225.7% | ||
| Q2 24 | 31.2% | -376.2% | ||
| Q1 24 | 16.1% | -573.0% |
| Q4 25 | 6.7% | 0.0% | ||
| Q3 25 | 4.3% | 0.0% | ||
| Q2 25 | 3.0% | 0.9% | ||
| Q1 25 | 0.6% | 35.6% | ||
| Q4 24 | 7.2% | 4.2% | ||
| Q3 24 | 1.0% | 0.0% | ||
| Q2 24 | 1.0% | 0.4% | ||
| Q1 24 | 4.7% | 3.2% |
| Q4 25 | 4.64× | -0.68× | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 0.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCML
Segment breakdown not available.
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
